NIKKEI 225
28,860.62 +405.02 (+1.42%) HANG SENG
23,974.13 -9.53 (-0.04%) CRUDE OIL
71.34 -0.71 (-0.99%) GOLD FUTURES
1,790.60 +5.90 (+0.33%) DOW
35,719.43 +492.40 (+1.40%) BTC-GBP
38,189.70 -569.47 (-1.47%)
Genomic Vision Société Anonyme (0QT4.L)
| Previous close | 0.2827 |
| Open | 0.2843 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.2843 - 0.2858 |
| 52-week range | 0.2843 - 0.2858 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | -0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1090 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Genomic Vision: Financial Information for the Third Quarter of 2021
BAGNEUX, France, October 28, 2021--Regulatory News: Genomic Vision (Paris:GV) (FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced its 9-month revenue and cash position at September 30, 2021.
- Business Wire
Genomic Vision Announces TeloSizer® Triathlon Program to Provide Academic Researchers With an Access Path to Molecular Combing Telomere Services
BAGNEUX, France, October 19, 2021--Regulatory News: Genomic Vision (Paris:GV) (the "Company" - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced the availability of TeloSizer® Triathlon, a program offering academic researchers complementary access to its new TeloSizer® services.
- Business Wire
Genomic Vision Strengthens Its Leadership Team With the Appointment of Thierry HUET as R&D Director
BAGNEUX, France, October 13, 2021--Regulatory News: Genomic Vision (the "Company" - FR0011799907 – GV) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of modifications in the genome, announced today the appointment of Dr. Thierry HUET as Director of Research and Development.
